STEINMAN LAWRENCE
SEC insider (Form 3/4/5 filer). CIK 0001132679. Director at Pasithea Therapeutics Corp. (KTTA) and 2 other issuers. 7 reported Form 4/5 transactions since Sep 2024; latest on May 1, 2026. Located in MIAMI BEACH, FL.
Companies STEINMAN LAWRENCE has filed insider reports for
- Pasithea Therapeutics Corp. (KTTA): Director
- 180 Life Sciences Corp. (ATNF): Director
- BioAtla, Inc. (BCAB): Director
STEINMAN LAWRENCE
CIK: 0001132679
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (7 total)
- May 1, 2026KTTA
Pasithea Therapeutics Corp.
AwardDirectStock Option (right to buy)
152.8K shares- - Nov 28, 2025KTTA
Pasithea Therapeutics Corp.
PurchaseDirect133.3K shares at avg. $0.75$100K - Oct 24, 2025KTTA
Pasithea Therapeutics Corp.
AwardDirectStock Option (right to buy)
242.9K shares- - Jun 18, 2025BCAB
BioAtla, Inc.
AwardDirect23.5K shares- - Jun 17, 2025ATNF
180 Life Sciences Corp.
AwardDirect45K shares- - Jun 17, 2025ATNF
180 Life Sciences Corp.
AwardDirect48.2K shares- - Feb 20, 2025ATNF
180 Life Sciences Corp.
AwardDirect65K shares-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| May 1, 2026 |  KTTA Pasithea Therapeutics Corp. | Award Stock Option (right to buy) | 152,783 | - | - | Direct |
| Nov 28, 2025 | KTTA Pasithea Therapeutics Corp. | Purchase | 133,333 | $0.75 | $100,000 | Direct |
| Oct 24, 2025 | KTTA Pasithea Therapeutics Corp. | Award Stock Option (right to buy) | 242,913 | - | - | Direct |
| Jun 18, 2025 |  BCAB BioAtla, Inc. | Award | 23,500 | - | - | Direct |
| Jun 17, 2025 |  ATNF 180 Life Sciences Corp. | Award | 44,959 | - | - | Direct |
| Jun 17, 2025 | ATNF 180 Life Sciences Corp. | Award | 48,198 | - | - | Direct |
| Feb 20, 2025 | ATNF 180 Life Sciences Corp. | Award | 65,000 | - | - | Direct |
1-7 of 7 transactions